According to Recipharm, there is significant market demand for global sterile capacity. But as the need to fill out the COVID-19 vaccine decreases, the festival among CDMOs will increase.
The Swedish progressive contract production (CDMO) organization, Recipharm, has made various investments around the world for its filling and finishing functions and functions.
In October, the company strengthened its sterile filling functions by investing in the generation of laboratory used for low-volume blow filling, filling and sealing (BFS) at its plant in Kaysersberg, France. In addition, CDMO signed a Memorandum of Understanding (MOU) in July 2021 to invest $500 million in the construction of a new filling and finishing plant, to be located on a 42-hectare site in Morocco. In the same month, Recipharm announced that it would build a filling and finishing facility in Uttarakhand, India, expanding its filling and finishing capacity to one billion sterile sets in line with the year.
However, as life returns and pandemic-related COVID-19 vaccine orders decline, as experienced by Sartorius, Danaher Corporation and Catalent, Recipharm told us that this would lead to a larger festival among CDMOs for large-scale projects.
Recipharm (R): Throughout 2022, we have noticed that CDMO’s sterile filling and completion capacity has increased significantly, and in 2023, we expect this trend to continue across the industry. For the new year, we may be expecting a festival of expansion among CDMOs for other high-volume, high-performance aseptic liquid filling projects.
A: 2022 has created a new market environment with significant supply chain constraints, peak inflation rates and lack of confidence in power that will last until 2023. In [2023], we expect continued strong demand. CDMOs will want to conscientiously manage their expansion trajectories and navigate a complex vendor scenario to continue to serve customers well.
A: A shift towards relationships with more regional (rather than global) suppliers is another vital trend that we plan to continue. the United States and China, to inspire the offshoring of sources.
A: There is abundant demand for sterile capacity in the European and African market, and we expect this to continue for the foreseeable future. With this in mind, we intend to continue investing in our capabilities and functions in the aseptic filling of liquid vials, prefilled syringes and freeze-drying at our network of sites in Italy, Germany and France. In Africa, we have the opportunity to expand in a short time, depending on incoming demand.
A: The increase in the amount of biologics entering the progression pipeline is one of the main drivers of this expansion in the demand for sterile filling. Biologics generally require parenteral administration; As such, they require an aseptic procedure and completion. As giant molecules, these biologics also present a challenge in the filtration procedure that will need to be addressed at the filling and completion stage.
A: Over the next few years, we will see an expansion in demand for sterile filling and finishing, especially for more complex dosing forms such as prefilled syringes, cartridges and freeze-dried products.
Second, we see more and more pharmaceutical corporations exploring self-administration of their products, for example through auto-injectors, wet mist inhalers, or nasal devices. All those devices require filling and filling, sterile or non-sterile, as well as gathering and packaging capabilities. This makes pharmaceutical corporations’ supply chains more complex, but the practical benefits of self-administered dosing bureaucracy increase the price for patients who need it. themselves, simplifying the supply chain for customers.
Categories: BioProcess Insider, Facilities & Capacity